Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499700 | 0.96 | FGFR1 (0.47) | FGFR1FGFR2 | |
| SCHEMBL19499687 | 0.95 | FGFR1 (0.49) | FGFR1FGFR2 | |
| SCHEMBL16071670 | 0.91 | FGFR1 (0.49) | FGFR1FGFR2 | |
| SCHEMBL19499694 | 0.88 | FGFR1 (0.47) | FGFR1FGFR2 | |
| SCHEMBL16993021 | 0.86 | FGFR1 (0.61) | FGFR1FGFR2 | |
| SCHEMBL19499704 | 0.85 | FGFR1 (0.59) | FGFR1FGFR2 | |
| SCHEMBL16993123 | 0.85 | FGFR1 (0.61) | FGFR1FGFR2 | |
| SCHEMBL16993309 | 0.85 | FGFR1 (0.63) | FGFR1FGFR2 | |
| SCHEMBL27265461 | 0.84 | USP30 (0.42) | — | |
| SCHEMBL17910146 | 0.84 | FGFR1 (0.63) | FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | FGFR1 4/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.